Endokrinologie der Intensivmedizin

Kernaussagen

• Neuroendokrine Anpassungen an akute Stressoren sind im Laufe der Evolution selektioniert worden und müssen daher zunächst als positiv für das Überleben schwerer Krankheiten oder Traumen angesehen werden.

• Diese Anpassungen verändern sich im prolongierten Verlauf kritischer Erkrankungen. Unklar bleibt, welche der Adaptationen in dieser Phase irrelevant für das Überleben sind und welche sich positiv oder eher negativ auf das Outcome auswirken.

• Für Patienten auf chirurgischen Intensivstationen wird die Einstellung des Glukosespiegels auf Werte unter 8,3 mmol/l (< 150 mg/dl) empfohlen.

• Vom Einsatz von Wachstumshormonen bei Intensivpatienten wird von den Fachgesellschaften abgeraten.

• Weder die Therapie mit T3 noch mit T4 wird für die akute oder prolongierte Phase kritischer Erkrankungen für die tägliche Routine empfohlen. Der Einsatz von TRH ist bisher noch experimentell.

• Literatur

• 1 Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001; 30: 695-728
• 2 Van den Berghe BG. The neuroendocrine response to stress is a dynamic process. Best Pract Res Clin Endocrinol Metab 2001; 15: 405-419
• 3 Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Pract Res Clin Endocrinol Metab 2001; 15: 533-551
• 4 Langouche L, Vander Perre S, Marques M et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 2013; 98: 1006-1013
• 5 Fan Y, Zhang AM, Xiao YB et al. Glucose-insulin-potassium therapy in adult patients undergoing cardiac surgery: A meta-analysis. Eur J Cardiothorac Surg 2011; 40: 192-199
• 6 Van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367
• 7 Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461
• 8 Vlasselaers D, Milants I, Desmet L et al. Intensive insulin therapy for patients in paediatric intensive care: A prospective, randomised controlled study. Lancet 2009; 373: 547-556
• 9 Vanhorebeek I, Langouche L. Molecular mechanisms behind clinical benefits of intensive insulin therapy during critical illness: Glucose versus insulin. Best Pract Res Clin Anaesthesiol 2009; 23: 449-459
• 10 NICE-SUGAR Study Investigators. Finfer S, Chittock DR et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-1297
• 11 Ellger B, Van den Berghe G. Tight glycaemic control: From bed to bench and back. Best Pract Res Clin Anaesthesiol 2009; 23: VII-IX
• 12 Preiser JC, Devos P, Chiolero R. Which factors influence glycemic control in the intensive care unit?. Curr Opin Clin Nutr Metab Care 2010; 13: 205-210
• 13 Siegelaar SE, Devries JH, Hoekstra JB. Patients with diabetes in the intensive care unit; not served by treatment, yet protected?. Critical Care 2010; 14: 126-127
• 14 Egi M, Bellomo R, Stachowski E et al. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology 2006; 105: 244-252
• 15 Vogelzang M, Loef BG, Regtien JG et al. Computer-assisted glucose control in critically ill patients. Intensive Care Med 2008; 34: 1421-1427
• 16 Wahl HG. How accurately do we measure blood glucose levels in intensive care unit (ICU) patients?. Best Pract Res Clin Anaesthesiol 2009; 23: 387-400
• 17 Duning T, Ellger B. Is hypoglycaemia dangerous?. Best Pract Res Clin Anaesthesiol 2009; 23: 473-485
• 18 Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: Risk factors and outcomes. Crit Care Med 2007; 35: 2262-2267
• 19 Duning T, van den Heuvel I, Dickmann A et al. Hypoglycemia aggravates critical illness-induced neurocognitive dysfunction. Diabetes Care 2010; 33: 639-644
• 20 Nobels F, Lecomte P, Deprez N et al. Tight glycaemic control: Clinical implementation of protocols. Best Pract Res Clin Anaesthesiol 2009; 23: 461-472
• 21 Mesotten D, Van den Berghe G. Glycemic targets and approaches to management of the patient with critical illness. Curr Diab Rep 2012; 12: 101-107
• 22 Van den Berghe BG, Baxter RC, Weekers F et al. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf) 2002; 56: 655-669
• 23 Elijah IE, Branski LK, Finnerty CC et al. The GH/IGF-1 system in critical illness. Best Pract Res Clin Endocrinol Metab 2011; 25: 759-767
• 24 Taylor BE, Buchman TG. Is there a role for growth hormone therapy in refractory critical illness?. Curr Opin Crit Care 2008; 14: 438-444
• 25 Mebis L, Van den Berghe G. Thyroid axis function and dysfunction in critical illness. Best Pract Res Clin Endocrinology Metab 2011; 25: 745-757
• 26 Barquist E, Kirton O. Adrenal insufficiency in the surgical intensive care unit patient. J Trauma 1997; 42: 27-31
• 27 Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287: 236-240
• 28 Pappa TA, Vagenakis AG, Alevizaki M. The nonthyroidal illness syndrome in the non-critically ill patient. Eur J Clin Invest 2011; 41: 212-220
• 29 Venkatesh B, Cohen J. Adrenocortical (dys)function in septic shock – a sick euadrenal state. Best Pract Res Clin Endocrinol Metab 2011; 25: 719-733
• 30 Gibbison B, Angelini GD, Lightman SL. Dynamic output and control of the hypothalamic-pituitary-adrenal axis in critical illness and major surgery. Br J Anaesth 2013;